Efficacy of Rituximab in Refractory Inflammatory Myopathies Associated with Anti- Synthetase Auto-Antibodies: An Open-Label, Phase II Trial
Fig 5
SF-36 scores measuring parameters of mobility.
For each score (ranging from 0 to 100) the mean values (± SD) are represented at different time points: baseline (M0); months 6, 12 and 18 after rituximab infusion (M6, M12 and M18). The asterisk represents a significant increase (more than 10 points) compared with baseline.